{
  "docId": "019de075-b7fd-707e-9848-cbfca2408f7c",
  "docSlug": "18b92232553b1610a38c1cd353f6efa7",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 28 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 28,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses a timeline-based process diagram to illustrate the clinical trial protocol.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-b7fd-707e-9848-cbfca2408f7c/12",
  "deckHref": "/decks/019de075-b7fd-707e-9848-cbfca2408f7c",
  "deckJsonHref": "/decks/019de075-b7fd-707e-9848-cbfca2408f7c.json",
  "deckAnchorHref": "/decks/019de075-b7fd-707e-9848-cbfca2408f7c#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.92,
        "x": 0.04,
        "y": 0.28
      },
      "kind": "diagram",
      "text": "Clinical trial timeline showing initial treatment vs step-down treatment phases",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "485876af-a6ce-429b-8c21-65f836dc447c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.73,
        "y": 0.78
      },
      "kind": "list",
      "text": "SECONDARY ENDPOINTS: Overall response, mortality at 84 days, safety, pharmacoeconomic impact",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2fbb0014-7ebe-4708-9891-99031b85d029",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.02,
        "y": 0.78
      },
      "kind": "list",
      "text": "IFIs in patients with LIMITED TREATMENT OPTIONS: Invasive candidiasis, candida cystitis, endemic mycoses, etc.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8d105231-1f94-43fc-a9b3-12c1eb8a7c8d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.22,
        "x": 0.49,
        "y": 0.78
      },
      "kind": "metric",
      "text": "PRIMARY ENDPOINT: All-cause mortality at 42 days",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "df043ec1-8393-4824-9124-07b09bb67ab6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.92,
        "x": 0.04,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "To assess the efficacy, safety, and tolerability of MAT2203 in patients with Invasive Aspergillosis; Patients will be randomized 2:1 to receive either oral MAT2203 as “step down” treatment after initial treatment with IV AMB (Experimental Arm) or Standard of Care (Comparator Arm)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79fe22a1-2dd7-4b26-bd13-a073b5a42520",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.92,
        "x": 0.04,
        "y": 0.21
      },
      "kind": "paragraph",
      "text": "Non-randomized experimental arm: patients with serious, life-threatening IFIs with limited treatment options will receive oral MAT2203 as “step down” treatment after initial treatment with IV AMB (or an echinocandin)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "83239030-9044-4a2c-a947-0e06b3d5fd02",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.04,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "*Numbers based on 20% NI margin and 85% power",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd7d2c9d-3cb6-4d32-a96c-c74ed6fcf4fd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.92,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "Phase III Aspergillosis/IFI Study – Preliminary Design (Subject to FDA Agreement)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f647ee4d-0b48-4c46-bc9f-ce9e01ccaa5b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "AIDA Model",
      "slug": "aida-model",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "68f027de-8b4c-4530-8629-a62e3fa91f90",
      "evidence": "The slide mentions a primary endpoint and secondary endpoints, which is a common structure for the AIDA model (Attention, Interest, Desire, Action)",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "f761fc1d-4a19-4525-97ea-2813cf233d11",
      "evidence": "The slide uses a horizontal timeline to depict the clinical trial phases.",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}